Martek Biosciences Corp.

Mr. Steve Dubin was appointed Chief Executive Officer in July 2006. He joined the Company in April 1992, holding a variety of positions including Chief Financial Officer, Treasurer, Secretary & General Counsel, and Senior Vice President of Business Development. In 2003, Mr. Dubin was appointed President of the Company. In these capacities, he was responsible for the Company's strategic planning, operations, finance, and sales and marketing groups. Prior to joining the Company, Mr. Dubin was employed in various positions at Suburban Bank (now a part of Bank of America) including Vice President of Suburban Capital Corporation, the bank's venture capital subsidiary. In this position, he helped lead Martek's initial round of institutional venture financing in 1986. Mr. Dubin currently serves in a variety of non-profit business leadership positions including the Tech Council of Maryland and MdBio, a private non-profit corporation that seeks to unify, empower and advance Maryland’s bioscience industry. Mr. Dubin holds a Bachelors degree from University of Maryland, College Park, and a Juris Doctor degree from the National Law Center at the George Washington University in Washington, D.C. He is a licensed CPA and a member of the Maryland Bar.

Mr. Abramson was appointed President in September 2006. He joined Martek in 2003 to lead the Business Development department. Prior to joining Martek, he was the Executive Vice President and General Counsel for U.S. Foodservice (1996 – 2003). In addition, Mr. Abramson was also the Executive Vice President for Legal Affairs at Ahold, U.S.A. (2000 – 2003). Mr. Abramson also served on the Board of Directors of U.S. Foodservice from 1994-2003. During his tenure with US Foodservice, he directed the acquisition efforts in which the Company’s business grew in excess of 1500%. Prior to joining U.S. Foodservice, Mr. Abramson was the President of a corporate law firm based in Columbia, Maryland, Levan, Schimel, Belman & Abramson, P.A, which is now part of Miles & Stockbridge. Mr. Abramson specialized in corporate matters, mergers and acquisitions. He has also served on the board of numerous non-profit community organizations, including serving as the Chairman of the Board of Trustees of Howard County General Hospital- A Member of Johns Hopkins Medicine, from 1993 to 1995. Mr. Abramson graduated from George Washington University in 1975, where he obtained a Bachelors of Business Administration in accounting. He received his Juris Doctor Degree, with honors, from the University of Maryland School of Law in 1978. Mr. Abramson is a member of the Maryland Bar.

Mr. Peter Nitze joined Martek in September 2005 as Senior Vice President and Chief Operating Officer. He began his career in finance at General Electric and has subsequently held positions of increasing responsibility in engineering, supply chain, operations and general management. Prior to joining Martek, Mr. Nitze held senior level operations positions at DRS Technologies, Regulatory DataCorp and business units of Honeywell International. He received his M.S. in Manufacturing Systems Engineering and Industrial Engineering from Stanford University and his B.A. from Harvard University.

Mr. Buzy joined Martek in March 1998 as Chief Financial Officer. Prior to joining Martek, Mr. Buzy spent 13 years with the accounting firm of Ernst & Young LLP, most recently as an audit partner in the Northern Virginia High Technology/Life Sciences Practice. Mr. Buzy is a Certified Public Accountant and a member of the American Institute of Certified Public Accountants. He received his B.S. in accounting from Salisbury State University.

Dr. Fealey has an extensive background in the consumer packaged goods industry in research and product development and in general management, including nearly three decades at The Procter and Gamble Company where he served as vice president of worldwide strategic planning, foods and beverages. Dr. Fealey also served as vice president of corporate research and development at The Coca-Cola Company where he led the creation of the Company’s strategic technology platforms to support newly established global growth objectives.

Mr. Feitel joined Martek in 2004 as Associate General Counsel and was elected to the position of Senior Vice President, General Counsel and Secretary in December 2006. In 2009, he was promoted to Executive Vice President, General Counsel and Secretary. From 2003 until joining Martek, he practiced law at Miles & Stockbridge P.C., where he had started his legal career in 1988. From 2000 to 2003, Mr. Feitel was the Vice President and General Counsel of BCE Emergis, an eCommerce service provider and a subsidiary of Bell Canada. Prior to BCE Emergis, Mr. Feitel worked for the Discovery Group, a Columbus, Ohio-based venture capital company, from 1997 through 2000. Mr. Feitel received his undergraduate degree from Duke University and his Juris Doctor from the Duke University School of Law in 1988.

Mr. Kelley has over 25 years experience in the Biotechnology, Pharmaceutical and Food manufacturing industry. He is currently VP of Manufacturing at Martek Biosciences Corporation. Prior to joining Market, Mr. Kelley worked for Bayer Corporation. During his 16 years at Bayer he managed an enzyme plant in Elkhart, Indiana, pharmaceutical production in Wuppertal, Germany and led the start up a multi-product biopharmaceutical plant in Berkeley, California. He serves as a Fund Manager for the Blue Grass Angel Venture Fund.

Mr. MacMaster served in various management positions at Merck & Co., Inc. (“Merck”) from 1961 to 1988, at which time he was appointed Senior Vice President responsible for ten divisions, including Manufacturing and Technology and Pharmaceutical Manufacturing. Mr. MacMaster retired from Merck in 1991 and currently serves as a Director for Neose Technologies, Inc. (biotechnology) and Stratton Mutual Funds. Mr. MacMaster has been a Director of Martek since 1993. His term expires in 2009.

Mr. D Andrea has served as Administrative General Partner of Valhalla Partners, a venture capital fund, since 2002. From 1999 to 2002, Mr. D Andrea served as the Chief Financial Officer of Advanced Switching Communications, Inc., a telecommunications equipment provider. From 1998 to 1999, Mr. D Andrea served as Chief Financial Officer of Call Technologies, Inc., a telecommunications software provider. From 1997 to 1998, Mr. D Andrea served as Chief Financial Officer of Yurie Systems, Inc., a provider of networking and telecommunications equipment. Mr. D Andrea has been a director of Martek since November 2006.

Robert Flanagan is Executive Vice President of Clark Enterprises, Inc., a Bethesda, Maryland-based holding company that is the ownership, investment, and asset management arm of the various Clark entities, which have interests in construction, real estate, and private equities. Through CNF Investments, LLC, the private equity investment division of Clark Enterprises, Inc., he manages investments in start-up and expansion stage companies and other private equity funds. Flanagan is a member of the board of directors of The Clark Construction Group, Inc., ILD Telecommunications, Martek BioSciences, Prestwick Pharmaceutical, Eagle Oil & Gas, and Marc Global Holdings. Prior to joining Clark, Flanagan was the treasurer, secretary, and member of the board of directors of Baltimore Orioles, Inc. and began his career in Washington, D.C., as a member of Arthur Andersen's audit division.

J. Neal Armstrong has served as a director since April 2007. Since February 2005, Mr. Armstrong has served as Vice President of Aspect Medical Systems, Inc., a developer and manufacturer of an anesthesia monitoring system. He was Vice President and Chief Financial Officer of Aspect Medical Systems, Inc. from 1996 to January 2005. Mr. Armstrong is also a director of deCODE genetics, Inc. Mr. Armstrong received a Bachelor of Business Administration and Accounting from the University of Texas and is a Certified Public Accountant.

Mr. Keller became a Director of Martek following his retirement as Senior Vice President of Sales and Marketing at the end of fiscal year 2005. Mr. Keller served as Martek’s Senior Vice President of Sales and Marketing from September 1997 to October 2005. Prior to joining Martek, Mr. Keller had been consulting after spending a 25-year career at Merck, most recently as Vice President of Sales from 1986 to 1993. In this position, he was responsible for all U.S. sales operations, including the direction of a support staff of 4,500 personnel and a sales volume of $4.2 billion. Some of the products introduced under Mr. Keller included Pepcid, Mefoxin, Primaxin, Vasotec, Mevocor, Zocor, Proscor and Prilosec. Mr. Keller has a M.S. degree from the University of Pittsburgh and a B.S. degree from Duquesne University. His term will expire in 2009.

Mr. Devine retired from public accounting in 2003 after a successful 24-year career primarily spent as a partner with Arthur Andersen LLP and later with Deloitte & Touche LLP. During his years at Arthur Andersen, Mr. Devine served in many technical leadership capacities including being a member of the firm’s worldwide technology industries technical consultation group and being the southeastern United States technical coordinator for the software industry. After his retirement from public accounting, Mr. Devine served from 2004 to 2007 as the chief financial officer of Secure Software, Inc., a software developer. Mr. Devine holds a master of business administration degree from Penn State University and a bachelor of arts degree from Rider College. His term expires in 2009.

Mrs. Kawalek retired in 2004 after serving for 25 years in various capacities at Quaker Oats, Inc., a consumer goods company and, since 2001, a business unit of PepsiCo. From 2002 until her retirement, she served as President of PepsiCo’s Quaker Foods division. In 2001, Mrs. Kawalek served as President of Quaker Oats’ U.S. Foods division and from 1997 through 2000, she served as President of the Hot Breakfast division. Mrs. Kawalek also serves as director for Kimball International, Inc. Mrs. Kawalek has been a director of Martek since January 2006. Her term expires in 2009.

Robert Mayer is Chairman and Chief Executive Officer of Genencor International. Previously, as Executive Vice President of Danisco, he served on Genencor's Board of Directors. He has held numerous management positions at Danisco since 1981. Bob holds a Masters in Engineering and a Ph.D. in Chemical Engineering.

Sandra Panem joined Cross Atlantic Partners in 2000 as a Managing Partner. Previously, she was President of Vector Fund Management, where she was responsible for the start-up, capital raising, and management of the asset management affiliate of Vector Securities International. Operations included the management of the Vector Later-Stage Equity Fund, L.P., and Vector Later-Stage Equity Fund II, L.P., private partnerships committing $240 million to equity investments in the emerging life science and healthcare industries. Prior to joining Vector, Dr. Panem served as Vice President and Portfolio Manager for the Oppenheimer Global BioTech Fund, a $200 million mutual fund that invested in public and private biotechnology companies. Prior to Oppenheimer, Dr. Panem was Vice President at Salomon Brothers, Inc. where she acted as a member of Salomon Brothers Venture Capital, a $40 million fund focused on early and later-stage life science and technology investments. Dr. Panem was also an Assistant Professor at the University of Chicago and a Fellow at the Brookings Institution, and is the author of several books and papers concerning the commercialization of new medical technologies. Currently, she holds directorships in Acorda Therapeutics, Labcyte, and GenomeQuest. She is a director of the New York Biotechnology Association. She received a B.S. Degree in Biochemistry ('66) and a Ph.D. in Microbiology ('70) from the University of Chicago.